Literature DB >> 21425263

Therapeutics for multiple sclerosis symptoms.

Aliza Bitton Ben-Zacharia1.   

Abstract

Symptoms management in multiple sclerosis is an integral part of its care. Accurate assessment and addressing the different symptoms provides increased quality of life among patients with multiple sclerosis. Multiple sclerosis symptoms may be identified as primary, secondary, or tertiary symptoms. Primary symptoms, such as weakness, sensory loss, and ataxia, are directly related to demyelination and axonal loss. Secondary symptoms, such as urinary tract infections as a result of urinary retention, are a result of the primary symptoms. Tertiary symptoms, such as reactive depression or social isolation, are a result of the social and psychological consequences of the disease. Common multiple sclerosis symptoms include fatigue and weakness; decreased balance, spasticity and gait problems; depression and cognitive issues; bladder, bowel, and sexual deficits; visual and sensory loss; and neuropathic pain. Less-common symptoms include dysarthria and dysphagia, vertigo, and tremors. Rare symptoms in multiple sclerosis include seizures, hearing loss, and paralysis. Symptom management includes nonpharmacological methods, such as rehabilitation and psychosocial support, and pharmacological methods, ie, medications and surgical procedures. The keys to symptom management are awareness, knowledge, and coordination of care. Symptoms have to be recognized and management needs to be individualized. Multiple sclerosis therapeutics include nonpharmacological strategies that consist of lifestyle modifications, rehabilitation, social support, counseling, and pharmacological agents or surgical procedures. The goal is vigilant management to improve quality of life and promote realistic expectations and hope.
© 2011 Mount Sinai School of Medicine.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21425263     DOI: 10.1002/msj.20245

Source DB:  PubMed          Journal:  Mt Sinai J Med        ISSN: 0027-2507


  8 in total

Review 1.  Menopause in multiple sclerosis: therapeutic considerations.

Authors:  Riley Bove; Tanuja Chitnis; Maria Houtchens
Journal:  J Neurol       Date:  2013-10-08       Impact factor: 4.849

2.  A Framework of Care in Multiple Sclerosis, Part 2: Symptomatic Care and Beyond.

Authors:  Scott D Newsome; Philip J Aliotta; Jacquelyn Bainbridge; Susan E Bennett; Gary Cutter; Kaylan Fenton; Fred Lublin; Dorothy Northrop; David Rintell; Bryan D Walker; Megan Weigel; Kathleen Zackowski; David E Jones
Journal:  Int J MS Care       Date:  2017 Jan-Feb

3.  Community qigong for People with Multiple Sclerosis: A Pragmatic Feasibility Study.

Authors:  Lita Buttolph; Joshua Corn; Douglas Hanes; Ryan Bradley; Angela Senders
Journal:  J Altern Complement Med       Date:  2021-03-26       Impact factor: 2.381

4.  Can meditation influence quality of life, depression, and disease outcome in multiple sclerosis? Findings from a large international web-based study.

Authors:  Adam B Levin; Emily J Hadgkiss; Tracey J Weiland; Claudia H Marck; Dania M van der Meer; Naresh G Pereira; George A Jelinek
Journal:  Behav Neurol       Date:  2014-11-12       Impact factor: 3.342

Review 5.  Regulatory T cells in multiple sclerosis and myasthenia gravis.

Authors:  K M Danikowski; S Jayaraman; B S Prabhakar
Journal:  J Neuroinflammation       Date:  2017-06-09       Impact factor: 8.322

Review 6.  Comprehensive Approach to Management of Multiple Sclerosis: Addressing Invisible Symptoms-A Narrative Review.

Authors:  Lynsey Lakin; Bryan E Davis; Cherie C Binns; Keisha M Currie; Mary R Rensel
Journal:  Neurol Ther       Date:  2021-04-20

Review 7.  Meditation as an adjunct to the management of multiple sclerosis.

Authors:  Adam B Levin; Emily J Hadgkiss; Tracey J Weiland; George A Jelinek
Journal:  Neurol Res Int       Date:  2014-07-01

Review 8.  Neurological Benefits, Clinical Challenges, and Neuropathologic Promise of Medical Marijuana: A Systematic Review of Cannabinoid Effects in Multiple Sclerosis and Experimental Models of Demyelination.

Authors:  Victor Longoria; Hannah Parcel; Bameelia Toma; Annu Minhas; Rana Zeine
Journal:  Biomedicines       Date:  2022-02-24
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.